Top

Published in:

01-01-2019 | Original Article

Prevalence of thyroid diseases in familial adenomatous polyposis: a systematic review and meta-analysis

Authors: Jirat Chenbhanich, Amporn Atsawarungruangkit, Sira Korpaisarn, Tanit Phupitakphol, Soravis Osataphan, Prasit Phowthongkum

Published in: Familial Cancer | Issue 1/2019

Abstract

Thyroid cancer (TC) is a known extra-intestinal manifestation and contributes to the mortality and morbidity in patients with familial adenomatous polyposis (FAP). Its exact prevalence is not well established and recent studies have shown an increasing number of TC in this patient population. The prevalence of benign thyroid masses and endocrinologic thyroid disorders are also poorly described. We conducted a systematic review and meta-analysis by using a random-effects model to characterize TC and estimated the prevalence of thyroid diseases in FAP patients. Twelve studies (n = 9821) were included. Pooled prevalence of TC, benign thyroid masses, and endocrinologic thyroid disorders in FAP were 2.6% [95% confidence interval (CI) 1.3–4.8], 48.8% [95% CI 33.8–64.0], and 6.9% [95% CI 4.5–10.3] respectively. Subgroup analyses revealed higher prevalence of TC in studies with fewer participants, studies that used screening ultrasound to diagnose TC, and studies that were published after 2002. TC diagnosis preceded the diagnosis of FAP in 34% of the patients. The means age at diagnosis of FAP and TC were 29 and 31 years, respectively. 95% of the patients were female and the most common pathology was of papillary subtype (83.3%). Most mutations (79.2%) were located at the 5′ end of APC gene. In summary, benign thyroid disorders are common in FAP, yet, TC is an uncommon phenomenon. Certain patient subset, such as young female with APC mutation at the 5′ end, might benefit from routine surveillance ultrasound.

Available only for authorised users

Groen EJ, Roos A, Muntinghe FL et al (2008) Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 15(9):2439–2450. https://doi.org/10.1245/s10434-008-9981-3 CrossRefPubMedPubMedCentral

Crail HW (1949) Multiple primary malignancies arising in the rectum, brain, and thyroid; report of a case. U S Nav Med Bull 49(1):123–128PubMed

Perrier ND, van Heerden JA, Goellner JR et al. (1998) Thyroid cancer in patients with familial adenomatous polyposis. World journal of surgery 22(7):738–742 (discussion 43)CrossRefPubMed

Bulow C, Bulow S (1997) Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The leeds castle polyposis group. Int J Colorectal Dis 12(4):240–242CrossRefPubMed

Howlader N, Noone AM, Krapcho M et al (2016) SEER Cancer Statistics Review, 1975–2013. National Cancer Institute, Bethesda

Steinhagen E, Guillem JG, Chang G et al (2012) The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin Colorectal Cancer 11(4):304–308. https://doi.org/10.1016/j.clcc.2012.01.006 CrossRefPubMed

Harach HR, Williams GT, Williams ED (1994) Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 25(6):549–561CrossRefPubMed

Tomoda C, Miyauchi A, Uruno T et al (2004) Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 28(9):886–889CrossRefPubMed

Herraiz M, Barbesino G, Faquin W et al (2007) Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 5(3):367–373. https://doi.org/10.1016/j.cgh.2006.10.019 CrossRefPubMed

10.

Herrera L, Carrel A, Rao U, Castillo N, Petrelli N (1989) Familial adenomatous polyposis in association with thyroiditis. Report of two cases. Dis Colon Rectum 32(10):893–896CrossRefPubMed

11.

Furuya-Kanamori L, Bell KJ, Clark J, Glasziou P, Doi SA (2016) Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol. https://doi.org/10.1200/JCO.2016.67.7419 CrossRefPubMed

12.

Miyoshi Y, Nagase H, Ando H et al. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1(4):229–233CrossRefPubMed

13.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z CrossRefPubMed

14.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557 CrossRefPubMedPubMedCentral

15.

Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis. Wiley, ChichesterCrossRef

16.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634CrossRefPubMedPubMedCentral

17.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed

18.

Plail RO, Bussey HJ, Glazer G, Thomson JP (1987) Adenomatous polyposis: an association with carcinoma of the thyroid. Br J Surg 74(5):377–380CrossRefPubMed

19.

van der Linde K, Vasen HF, van Vliet AC (1998) Occurrence of thyroid carcinoma in Dutch patients with familial adenomatous polyposis: an epidemiological study and report of new cases. Eur J Gastroenterol Hepatol 10(9):777–781CrossRefPubMed

20.

Ho JW, Chu KM, Tse CW, Yuen ST (2002) Phenotype and management of patients with familial adenomatous polyposis in Hong Kong: perspective of the Hereditary Gastrointestinal Cancer Registry. Hong Kong medical journal = Xianggang yi xue za zhi/Hong Kong. Acad Med 8(5):342–347

21.

Truta B, Allen BA, Conrad PG et al. (2003) Genotype and phenotype of patients with both familial adenomatous polyposis and thyroid carcinoma. Familial Cancer 2(2):95–99CrossRefPubMed

22.

Martayan A, Sanchez-Mete L, Baldelli R et al (2010) Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: a novel APC germline mutation. J Endocrinol Investig 33(9):603–606CrossRef

23.

Steinhagen E, Hui VW, Levy RA et al (2014) Results of a prospective thyroid ultrasound screening program in adenomatous polyposis patients. Am J Surg 208(5):764–769. https://doi.org/10.1016/j.amjsurg.2014.03.012 CrossRefPubMed

24.

Feng X, Milas M, O’Malley M et al (2015) Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance. Thyroid 25(3):325–332. https://doi.org/10.1089/thy.2014.0107 CrossRefPubMed

25.

Casellas-Cabrera N, Diaz-Algorri Y, Carlo-Chevere VJ et al (2016) Risk of thyroid cancer among Caribbean Hispanic patients with familial adenomatous polyposis. Familial Cancer 15(2):267–274. https://doi.org/10.1007/s10689-015-9862-4 CrossRefPubMedPubMedCentral

26.

Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140(4):317–322. https://doi.org/10.1001/jamaoto.2014.1 CrossRefPubMed

27.

Cetta F, Ugolini G, Barellini L, Civitelli S, Carmellini M (2011) FAP associated cribriform morular variant of PTC: striking female prevalence and indolent course. Endocr J 58(9):817–818CrossRefPubMed

28.

Harb WJ, Sturgis EM (2009) Differentiated thyroid cancer associated with intestinal polyposis syndromes: a review. Head Neck 31(11):1511–1519. https://doi.org/10.1002/hed.21156 CrossRefPubMed

29.

Pradhan D, Sharma A, Mohanty SK (2015) Cribriform-morular variant of papillary thyroid carcinoma. Pathol Res Pract 211(10):712–716. https://doi.org/10.1016/j.prp.2015.04.011 CrossRefPubMed

30.

Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral

31.

Uchino S, Ishikawa H, Miyauchi A et al (2016) Age- and gender-specific risk of thyroid cancer in patients with familial adenomatous polyposis. J Clin Endocrinol Metab 101(12):4611–4617. https://doi.org/10.1210/jc.2016-2043 CrossRefPubMed

32.

Gerfo PL, Chabot J, Gazetas P (1990) The intraoperative incidence of detectable bilateral and multicentric disease in papillary cancer of the thyroid. Surgery 108(6):958–962 (discussion 62-3)PubMed

33.

Septer S, Slowik V, Morgan R, Dai H, Attard T (2013) Thyroid cancer complicating familial adenomatous polyposis: mutation spectrum of at-risk individuals. Hered Cancer Clin Pract 11(1):13. https://doi.org/10.1186/1897-4287-11-13 CrossRefPubMedPubMedCentral

34.

Cetta F, Montalto G, Gori M, Curia MC, Cama A, Olschwang S (2000) Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 85(1):286–292. https://doi.org/10.1210/jcem.85.1.6254 CrossRefPubMed

35.

Cetta F, Chiappetta G, Melillo RM et al (1998) The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. J Clin Endocrinol Metab 83(3):1003–1006. https://doi.org/10.1210/jcem.83.3.4614 CrossRefPubMed

36.

Ghorbanoghli Z, Bastiaansen BA, Langers AM et al (2017) Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis. J Med Genet. https://doi.org/10.1136/jmedgenet-2017-104545 CrossRefPubMed

37.

Vanderpump MP (2011) The epidemiology of thyroid disease. Br Med Bull 99:39–51. https://doi.org/10.1093/bmb/ldr030 CrossRefPubMed

38.

Staniforth JU, Erdirimanne S, Eslick GD (2016) Thyroid carcinoma in Graves’ disease: a meta-analysis. Int J Surg 27:118–125. https://doi.org/10.1016/j.ijsu.2015.11.027 CrossRefPubMed

39.

Lee J-H, Kim Y, Choi J-W, Kim Y-S (2013) The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 168(3):343–349. https://doi.org/10.1530/eje-12-0903 CrossRefPubMed

40.

Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L (2016) Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 375(7):614–617. https://doi.org/10.1056/NEJMp1604412 CrossRefPubMed

41.

Iwama T, Mishima Y, Utsunomiya J (1993) The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 217(2):101–108CrossRefPubMedPubMedCentral

42.

Gibbons DC, Sinha A, Phillips RK, Clark SK (2011) Colorectal cancer: no longer the issue in familial adenomatous polyposis? Familial Cancer 10(1):11–20. https://doi.org/10.1007/s10689-010-9394-x CrossRefPubMed

43.

de Campos FG, Perez RO, Imperiale AR, Seid VE, Nahas SC, Cecconello I (2010) Evaluating causes of death in familial adenomatous polyposis. J Gastrointest Surg 14(12):1943–1949. https://doi.org/10.1007/s11605-010-1288-6 CrossRefPubMed

44.

Syngal S, Brand RE, Church JM et al. (2015) ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110(2):223–262. https://doi.org/10.1038/ajg.2014.435 CrossRefPubMedPubMedCentral

45.

Force USPST, Bibbins-Domingo K, Grossman DC et al (2017) Screening for thyroid cancer: US preventive services task force recommendation statement. JAMA 317(18):1882–1887. https://doi.org/10.1001/jama.2017.4011 CrossRefPubMed

46.

Mohammadzadeh Z, Ghazisaeedi M, Nahvijou A, Kalhori SR, Davoodi S, Zendehdel K (2017) Systematic review of hospital based cancer registries (HBCRs): necessary tool to improve quality of care in cancer patients. Asian Pac J Cancer Prev 18(8):2027–2033. https://doi.org/10.22034/APJCP.2017.18.8.2027 CrossRefPubMedPubMedCentral

Title: Prevalence of thyroid diseases in familial adenomatous polyposis: a systematic review and meta-analysis
Authors: Jirat Chenbhanich
Amporn Atsawarungruangkit
Sira Korpaisarn
Tanit Phupitakphol
Soravis Osataphan
Prasit Phowthongkum
Publication date: 01-01-2019
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 1/2019
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-018-0085-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori

Report of a bi-allelic truncating germline mutation in TP53

Reminders of cancer risk and pain catastrophizing: relationships with cancer worry and perceived risk in women with a first-degree relative with breast cancer

Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy

Hemangioblastoma in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome: a phenotypic overlap between VHL and HLRCC Syndromes

Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer